Avnet, Inc. (AVT)

NASDAQ

$49.28

-$0.64 (1.28%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$49.06$50.44

Open $50.08

52 Week Range

$39.22$57.24

Previous Close $49.92

Market Cap4.01B

Volume483.62K

Avg Volume882.69K

P/E (TTM)17.55

EPS (TTM)$2.81

Dividend / Yield$1.36 (2.76%)

Dividend Streak12 years

Latest Press Releases for Avnet, Inc.

NOV242025

Avnet to Participate in the Nasdaq Investor Conference on December 9

Source: Business Wire•22 days ago

PHOENIX--(BUSINESS WIRE)-- #Avnet--Avnet to participate in the Nasdaq Investor Conference on December 9....

NOV202025

Avnet Declares Regular Quarterly Dividend

Source: Business Wire•25 days ago

PHOENIX--(BUSINESS WIRE)-- #Avnet--Avnet declares regular quarterly dividend....

OCT292025

Avnet Reports First Quarter 2026 Financial Results

Source: Business Wire•48 days ago

PHOENIX--(BUSINESS WIRE)-- #Avnet--Avnet reports first quarter 2026 financial results....

OCT152025

Avnet to Report First Quarter Fiscal Year 2026 Earnings on October 29

Source: Business Wire•62 days ago

PHOENIX--(BUSINESS WIRE)-- #Avnet--Avnet to report first quarter fiscal year 2026 earnings on October 29....

OCT72025

Dycom Industries, Inc. Appoints Phillip R. Gallagher to Board of Directors

Source: GlobeNewsWire•69 days ago

WEST PALM BEACH, Fla., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Dycom Industries, Inc. (NYSE: DY) today announced the appointment of Phillip R....

OCT62025

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

Source: GlobeNewsWire•71 days ago

LONDON and REYKJAVIK, Iceland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe and ...

OCT62025

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

Source: GlobeNewsWire•71 days ago

LONDON, UK and REYKJAVIK, ICELAND (OCTOBER 6, 2025) — Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe and Alvotech (...

SEP222025

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®

Source: GlobeNewsWire•85 days ago

REYKJAVIK, Iceland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Medicines Agenc...

SEP222025

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®

Source: GlobeNewsWire•85 days ago

REYKJAVIK, ICELAND (September 22, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Medicines Agency's (EMA) Co...